Member Info for share12345

rns out

3v1
not small buys going through

here we go

buyer on this
pick up bit my bit

15:27:15 63.00 15,853 Buy* 60.00 64.00 9,987
28-Aug-20 15:14:43 63.00 7,916 Buy* 60.00 64.00 4,987
28-Aug-20 15:07:41 63.00 15,853 Buy* 60.00 64.00 9,987

tick must be on the way

be nice to a pickup in the sp now

place orders only

looking good

Price Monitoring Extension

news may be soon

a lots of big buys to day.
people are happy to hold on this

just sit and hold

The Company will secure additional quantities of the vaccine to be distributed to the private pay market in Bangladesh.

got to be init to win it

Mr Adar C Poonawalla, Chief Executive Officer of Serum Institute of India and Shayan F Rahman, Principal of Beximco Pharmaceuticals jointly commented:



"We are excited to bring together two of the leading pharma companies in India and Bangladesh with the scale and capabilities to bring a hugely promising treatment to the people who need it the most. Between us, we can go a long way towards helping to mitigate the health crisis caused by the COVID-19 pandemic."

will prioritise Bangladesh to be one of the first countries to receive an agreed quantity of doses once the vaccine receives all necessary regulatory approvals.

SII has partnered with AstraZeneca, the Gates Foundation and Gavi, to produce more than a billion doses of a vaccine for global supply. Under the terms of the planned arrangement, Beximco will make a financial contribution to advance the development of the vaccine which will be adjusted based on the vaccine price.

Overview
Contents

The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players – from pharma and biotech firms to academic institutions and government agencies – have thrown their hats in the ring.

CLOSEAbout Beximco Pharmaceuticals LimitedBeximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since itsinception in 1976, the Company remains committed to health and wellbeing of people across all thecontinents by providing access to contemporary medicines. Company's broad portfolio of genericsencompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids,metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectable,nebulizer solutions, oral soluble films etc. The Company also undertakes contract manufacturing formultinational and leading global generic pharmaceutical companies.Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities ofUSA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint inmore than 50 countries. More than 4,500 employees are driving the company towards achieving its aspirationto be among the most admired companies in the world.This information is provided by RNS, t